Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma

Expert Review of Molecular Diagnostics

Volumn 14, Issue 5, 2014, Pages 535-548

  Fatima, Sarwat ^a,b   Luk, John M ^b   Poon, Ronnie T P ^b   Lee, Nikki P ^b  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

AFP; Diagnosis; Dickkopfs; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; AXIN; AZACITIDINE; BETA CATENIN; BETA TRANSDUCIN REPEAT CONTAINING PROTEIN; DECARBOXYPROTHROMBIN; DICKKOPF 1 PROTEIN; DICKKOPF 2 PROTEIN; DICKKOPF 3 PROTEIN; DICKKOPF 4 PROTEIN; FLUOROURACIL; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MICRORNA 122; MICRORNA 155; MICRORNA 29A; UNCLASSIFIED DRUG; AFP PROTEIN, HUMAN; DKK1 PROTEIN, HUMAN; SIGNAL PEPTIDE; TUMOR MARKER;

APOPTOSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC LIVER DISEASE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; DOWN REGULATION; ESOPHAGUS CANCER; GENE OVEREXPRESSION; GOLD STANDARD; GYNECOLOGIC CANCER; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; MISSENSE MUTATION; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN DEFECT; PROTEIN DYSREGULATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; UBIQUITINATION; WNT SIGNALING PATHWAY; BLOOD; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM;

ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS;

EID: 84901271684     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.915747     Document Type: Review

References (139)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61(2):69-90
2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence. mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27(9):1485-91
3. Kemp W, Pianko S, Nguyen S, et al. Survival in hepatocellular carcinoma: Impact of screening and etiology of liver disease. J Gastroenterol Hepatol 2005;20(6):873-81 (Pubitemid 40897168
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399):1907-17 (Pubitemid 37518510
5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004;127(5 Suppl 1): S35-50
6. Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 2009; 29(Suppl 1):143-7
7. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3-And 6-month periodicities. Hepatology 2011; 54(6):1987-97
8. Ikeda K, Saitoh S, Tsubota A, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993;71(1):19-25 (Pubitemid 23019276
9. Ciccarelli O, Lai Q, Goffette P, et al. Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria. Transpl Int 2012;25(8):867-75
10. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37(2):429-42 (Pubitemid 36152543
11. Zhang XF, Lai EC, Kang XY, et al. Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and a monitor of recurrence of hepatocellular carcinoma after curative liver resection. Ann Surg Oncol 2011;18(8): 2218-23
12. Morimoto M, Numata K, Nozaki A, et al. Novel Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein: A biomarker of hepatocellular carcinoma recurrence in patients with low alpha-fetoprotein concentrations. Int J Clin Oncol 2012; 17(4):373-9
13. Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009;100(8): 1403-7
14. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology 2003;37(5): 1114-21 (Pubitemid 36538688
15. Matsubara M, Shiraha H, Kataoka J, et al. Des-gamma-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27(10):1602-8
16. Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma. Gut 2010; 59(12):1687-93
17. Sun S, Poon RT, Lee NP, et al. Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (
18. Chen L, Ho DW, Lee NP, et al. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann Surg Oncol 2010;17(9):2518-25
19. Chon YE, Choi GH, Lee MH, et al. Combined measurement of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer 2012;131(10):2332-41
20. Liu AM, Yao TJ, Wang W, et al. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: A retrospective cohort study. BMJ Open 2012;2(2): E000825
21. Li LM, Hu ZB, Zhou ZX, et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 2010;70(23):9798-807
22. Qu KZ, Zhang K, Li H, et al. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol 2011;45(4): 355-60
23. Fatima S, Lee NP, Luk JM. Dickkopfs and Wnt/beta-catenin signalling in liver cancer. World J Clin Oncol 2011;2(8):311-25
24. McLin VA, Rankin SA, Zorn AM. Repression of Wnt/beta-catenin signaling in the anterior endoderm is essential for liver and pancreas development. Development 2007;134(12):2207-17 (Pubitemid 47010010
25. Cadigan KM, Liu YI. Wnt signaling: Complexity at the surface. J Cell Sci 2006; 119(Pt 3):395-402
26. Suzuki T, Yano H, Nakashima Y, et al. Beta-catenin expression in hepatocellular carcinoma: A possible participation of beta-catenin in the dedifferentiation process. J Gastroenterol Hepatol 2002;17(9): 994-1000
27. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: Clinicopathologic and prognostic significance. Cancer 2001; 92(1):136-45 (Pubitemid 32623050
28. Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol 1999;155(6):1795-801
29. Nhieu JT, Renard CA, Wei Y, et al. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155(3):703-10 (Pubitemid 29426815
30. Kondo Y, Kanai Y, Sakamoto M, et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res 1999;90(12):1301-9 (Pubitemid 30032067
31. Inagawa S, Itabashi M, Adachi S, et al. Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: Correlation with tumor progression and postoperative survival. Clin Cancer Res 2002;8(2):450-6 (Pubitemid 34193964
32. Cieply B, Zeng G, Proverbs-Singh T, et al. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology 2009;49(3):821-31
33. Kim M, Lee HC, Tsedensodnom O, et al. Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 2008;48(5):780-91
34. Bengochea A, de Souza MM, Lefrancois L, et al. Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer 2008; 99(1):143-50 (Pubitemid 351920222
35. Merle P, de la Monte S, Kim M, et al. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology 2004;127(4):1110-22 (Pubitemid 39345880
36. Csepregi A, Rocken C, Hoffmann J, et al. APC promoter methylation and protein expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008;134(5):579-89
37. Lee S, Lee HJ, Kim JH, et al. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;163(4):1371-8 (Pubitemid 37175085
38. Satoh S, Daigo Y, Furukawa Y, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet 2000;24(3):245-50 (Pubitemid 30132191
39. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002;21(31):4863-71
40. Chan DW, Chan CY, Yam JW, et al. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology 2006;131(4): 1218-27 (Pubitemid 44515098
41. Yau TO, Chan CY, Chan KL, et al. HDPR1, a novel inhibitor of the WNT/beta-catenin signaling, is frequently downregulated in hepatocellular carcinoma: Involvement of methylation-mediated gene silencing. Oncogene 2005;24(9):1607-14
42. Pang R, Yuen J, Yuen MF, et al. PIN1 overexpression and beta-catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. Oncogene 2004;23(23):4182-6 (Pubitemid 38747951
43. Krupnik VE, Sharp JD, Jiang C, et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999; 238(2):301-13 (Pubitemid 29447031
44. Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 1998;391(6665): 357-62 (Pubitemid 28093502
45. Mukhopadhyay M, Shtrom S, Rodriguez-Esteban C, et al. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev Cell 2001;1(3):423-34 (Pubitemid 33586091
46. Semenov MV, Tamai K, Brott BK, et al. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001; 11(12):951-61 (Pubitemid 32589186
47. Yamamoto H, Sakane H, Michiue T, Kikuchi A. Wnt3a and Dkk1 regulate distinct internalization pathways of LRP6 to tune the activation of beta-catenin signaling. Dev Cell 2008;15(1):37-48 (Pubitemid 351895596
48. Ellwanger K, Saito H, Clement-Lacroix P, et al. Targeted disruption of the Wnt regulator Kremen induces limb defects and high bone density. Mol Cell Biol 2008; 28(15):4875-82
49. Wang K, Zhang Y, Li X, et al. Characterization of the Kremen-binding site on Dkk1 and elucidation of the role of Kremen in Dkk-mediated Wnt antagonism. J Biol Chem 2008;283(34):23371-5
50. Aguilera O, Fraga MF, Ballestar E, et al. Epigenetic inactivation of the Wnt antagonist DICKKOPF-1 (DKK-1) gene in human colorectal cancer. Oncogene 2006; 25(29):4116-21 (Pubitemid 44024874
51. Taniguchi H, Yamamoto H, Hirata T, et al. Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 2005;24(53):7946-52 (Pubitemid 41715201
52. Forget MA, Turcotte S, Beauseigle D, et al. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types. Br J Cancer 2007;96(4):646-53
53. Xu WH, Liu ZB, Yang C, et al. Expression of dickkopf-1 and beta-catenin related to the prognosis of breast cancer patients with triple negative phenotype. PLoS One 2012; 7(5):e37624
54. Wang S, Zhang S. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Clin Exp Metastasis 2011;28(6):581-91
55. Tung EK, Mak CK, Fatima S, et al. Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. Liver Int 2011;31(10):1494-504
56. Sato N, Yamabuki T, Takano A, et al. Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy. Cancer Res 2010; 70(13):5326-36
57. Mao B, Niehrs C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene 2003;302(1-2): 179-83 (Pubitemid 36078410
58. Pendas-Franco N, Garcia JM, Pena C, et al. DICKKOPF-4 is induced by TCF/betacatenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 2008;27(32):4467-77
59. Yu B, Yang X, Xu Y, et al. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol 2009; 50(5):948-57
60. Hoang BH, Kubo T, Healey JH, et al. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res 2004;64(8):2734-9 (Pubitemid 38500609
61. Yue W, Sun Q, Dacic S, et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008;29(1): 84-92 (Pubitemid 351201745
62. Lee EJ, Jo M, Rho SB, et al. Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer 2009;124(2):287-97
63. Patil MA, Chua MS, Pan KH, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene 2005; 24(23):3737-47 (Pubitemid 40826873
64. Sheng SL, Huang G, Yu B, Qin WX. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem 2009;55(9): 1656-64
65. Lee HS, Lee HE, Park DJ, et al. Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta 2012;413(21-22): 1753-60
66. Jiang T, Wang S, Huang L, Zhang S. Clinical significance of serum DKK-1 in patients with gynecological cancer. Int J Gynecol Cancer 2009;19(7):1177-81
67. Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: A large-scale, multicentre study. Lancet Oncol 2012;13(8):817-26
68. Yamabuki T, Takano A, Hayama S, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res 2007; 67(6):2517-25 (Pubitemid 46548936
69. Taura N, Yatsuhashi H, Hamasaki K, et al. Increasing hepatitis C virus-Associated hepatocellular carcinoma mortality and aging: Long term trends in Japan. Hepatol Res 2006;34(2):130-4 (Pubitemid 43137563
70. Hsu HC, Jeng YM, Mao TL, et al. Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. Am J Pathol 2000; 157(3):763-70
71. Hiotis SP, Rahbari NN, Villanueva GA, et al. Hepatitis B vs. hepatitis C infection on viral hepatitis-Associated hepatocellular carcinoma. BMC Gastroenterol 2012;12:64
72. Kim W, Oe Lim S, et al. Comparison of proteome between hepatitis B virus-And hepatitis C virus-Associated hepatocellular carcinoma. Clin Cancer Res 2003;9(15): 5493-500 (Pubitemid 37499467
73. Lee CF, Ling ZQ, Zhao T, Lee KR. Distinct expression patterns in hepatitis B virus-And hepatitis C virus-infected hepatocellular carcinoma. World J Gastroenterol 2008;14(39):6072-7
74. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus-And hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res 2002;62(14):3939-44 (Pubitemid 34791056
75. Okabe H, Satoh S, Kato T, et al. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: Identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61(5): 2129-37 (Pubitemid 32692038
76. Nomura F, Ishijima M, Horikoshi A, et al. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: Comparison of the conventional enzyme immunoassay and two modified methods. Am J Gastroenterol 1996;91(7):1380-3 (Pubitemid 26236374
77. Shimauchi Y, Tanaka M, Kuromatsu R, et al. A simultaneous monitoring of Lens culinaris agglutinin A-reactive alphafetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep 2000;7(2): 249-56
78. Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 2002; 62(Suppl 1):57-63 (Pubitemid 34702021
79. Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002;17(7):772-8 (Pubitemid 34779738
80. Okuda H, Saito A, Haruyama K, et al. Unique clinicopathological features of patients with primary malignant hepatic tumors who are seropositive for lectin-reactive alpha-fetoprotein alone: Report of five cases. J Gastroenterol Hepatol 2004; 19(1):113-14 (Pubitemid 38130618
81. Okuda H, Saito A, Shiratori K, et al. Clinicopathologic features of patients with primary malignant hepatic tumors seropositive for alpha-fetoprotein-L3 alone in comparison with other patients seropositive for alpha-fetoprotein-L3. J Gastroenterol Hepatol 2005;20(5):759-64 (Pubitemid 40733372
82. Sterling RK, Jeffers L, Gordon F, et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 2009;7(1):104-13
83. Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 2009;137(1): 110-18
84. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci 2007;52(3):776-82
85. Tang W, Miki K, Kokudo N, et al. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol 2003; 22(5):969-75
86. Hamamura K, Shiratori Y, Shiina S, et al. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000;88(7): 1557-64 (Pubitemid 30183140
87. Gotoh M, Nakatani T, Masuda T, et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol 2003;33(10):522-6 (Pubitemid 43115246
88. Tang W, Kokudo N, Sugawara Y, et al. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: Association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep 2005;13(1):25-30
89. Ji J, Yamashita T, Wang XW. Wnt/betacatenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci 2011;1(1):4
90. Xu J, Zhu X, Wu L, et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/betacatenin pathway. Liver Int 2012;32(5): 752-60
91. Zhang Y, Wei W, Cheng N, et al. Hepatitis C. Virus-induced upregulation of miR-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012; 56(5):1631-40
92. Ladeiro Y, Couchy G, Balabaud C, et al. MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 2008;47(6): 1955-63 (Pubitemid 351952843
93. Poy MN, Eliasson L, Krutzfeldt J, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432(7014):226-30 (Pubitemid 39545853
94. Kapinas K, Kessler C, Ricks T, et al. miR-29 modulates Wnt signaling in human osteoblasts through a positive feedback loop. J Biol Chem 2010;285(33):25221-31
95. Baron R, Rawadi G, Roman-Roman S. Wnt signaling: A key regulator of bone mass. Curr Top Dev Biol 2006;76:103-27 (Pubitemid 44760540
96. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 2008;42(4):669-80
97. Kaiser M, Mieth M, Liebisch P, et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008;80(6):490-4 (Pubitemid 351677464
98. Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006;119(7):1728-31 (Pubitemid 44258784
99. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349(26):2483-94 (Pubitemid 38010074
100. Heider U, Kaiser M, Mieth M, et al. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment. Eur J Haematol 2009;82(1):31-8
101. Voorzanger-Rousselot N, Goehrig D, Journe F, et al. Increased Dickkopf-1 expression in breast cancer bone metastases. Br J Cancer 2007;97(7):964-70 (Pubitemid 47519305
102. Katyal S, Oliver JH 3rd, Peterson MS, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216(3): 698-703 (Pubitemid 30660840
103. Kemik O, Kemik AS, Sumer A, et al. Relationship between clinicopathologic variables and serum and tissue levels of dickkopf-1 in patients with rectal cancer. J Investig Med 2011;59(6):947-50
104. Lee HS, Lee HE, Park do J, et al. Clinical significance of serum and tissue Dickkopf-1 levels in patients with gastric cancer. Clin Chim Acta 2012;413(21-22): 1753-60
105. Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 2009;114(2):371-9
106. Qian J, Zheng Y, Zheng C, et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012;119(1):161-9
107. Yang B, Du Z, Gao YT, et al. Methylation of Dickkopf-3 as a prognostic factor in cirrhosis-related hepatocellular carcinoma. World J Gastroenterol 2010;16(6):755-63
108. Sato H, Suzuki H, Toyota M, et al. Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. Carcinogenesis 2007;28(12):2459-66 (Pubitemid 350238947
109. Hirata H, Hinoda Y, Nakajima K, et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin Cancer Res 2009;15(18): 5678-87
110. Zhu J, Zhang S, Gu L, Di W. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. Carcinogenesis 2012;33(12):2334-43
111. Tsuji T, Miyazaki M, Sakaguchi M, et al. A REIC gene shows down-regulation in human immortalized cells and human tumor-derived cell lines. Biochem Biophys Res Commun 2000;268(1):20-4 (Pubitemid 30116603
112. Hsieh SY, Hsieh PS, Chiu CT, Chen WY. Dickkopf-3/REIC functions as a suppressor gene of tumor growth. Oncogene 2004; 23(57):9183-9
113. Calvisi DF, Ladu S, Gorden A, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007;117(9): 2713-22 (Pubitemid 47494371
114. Gu YM, Ma YH, Zhao WG, Chen J. Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro. World J Gastroenterol 2011;17(33):3810-17
115. Veeck J, Wild PJ, Fuchs T, et al. Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer. BMC Cancer 2009;9:217
116. Yu J, Tao Q, Cheng YY, et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009;115(1):49-60
117. Licchesi JD, Westra WH, Hooker CM, et al. Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung. Carcinogenesis 2008; 29(5):895-904 (Pubitemid 351982232
118. Untergasser G, Steurer M, Zimmermann M, et al. The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. Int J Cancer 2008; 122(7):1539-47 (Pubitemid 351294962
119. Zitt M, Untergasser G, Amberger A, et al. Dickkopf-3 as a new potential marker for neoangiogenesis in colorectal cancer: Expression in cancer tissue and adjacent non-cancerous tissue. Dis Markers 2008; 24(2):101-9
120. Fong D, Hermann M, Untergasser G, et al. Dkk-3 expression in the tumor endothelium: A novel prognostic marker of pancreatic adenocarcinomas. Cancer Sci 2009;100(8):1414-20
121. Jiang T, Huang L, Wang S, Zhang S. Clinical significance of serum Dkk-3 in patients with gynecological cancer. J Obstet Gynaecol Res 2010;36(4):769-73
122. Zenzmaier C, Heitz M, Klocker H, et al. Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients. J Transl Med 2011;9:193
123. Zenzmaier C, Untergasser G, Hermann M, et al. Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue. Prostate 2008;68(5):540-7 (Pubitemid 351500214
124. Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001;61(4):1659-65 (Pubitemid 34292602
125. Kloten V, Becker B, Winner K, et al. Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res 2013;15(1):R4
126. Urakami S, Shiina H, Enokida H, et al. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Clin Cancer Res 2006;12(23): 6989-97 (Pubitemid 44974494
127. Liu JB, Qiang FL, Dong J, et al. Plasma DNA methylation of Wnt antagonists predicts recurrence of esophageal squamous cell carcinoma. World J Gastroenterol 2011; 17(44):4917-21
128. Fatima S, Lee NP, Tsang FH, et al. Dickkopf 4 (DKK4) acts on Wnt/betacatenin pathway by influencing beta-catenin in hepatocellular carcinoma. Oncogene 2012;31(38):4233-44
129. Matsui A, Yamaguchi T, Maekawa S, et al. DICKKOPF-4 and-2 genes are upregulated in human colorectal cancer. Cancer Sci 2009;100(10):1923-30
130. Baehs S, Herbst A, Thieme SE, et al. Dickkopf-4 is frequently down-regulated and inhibits growth of colorectal cancer cells. Cancer Lett 2009;276(2):152-9
131. Hirata H, Hinoda Y, Majid S, et al. DICKKOPF-4 activates the noncanonical c-Jun-NH2 kinase signaling pathway while inhibiting the Wnt-canonical pathway in human renal cell carcinoma. Cancer 2011; 117(8):1649-60
132. Xi Y, Formentini A, Nakajima G, et al. Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncol Rep 2008;19(1): 257-62 (Pubitemid 351176158
133. Ebert MP, Tanzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N Engl J Med 2012; 366(1):44-53
134. Noda T, Nagano H, Takemasa I, et al. Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-Alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. Br J Cancer 2009;100(10):1647-58
135. Nagano H, Miyamoto A, Wada H, et al. Interferon-Alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 2007;110(11): 2493-501 (Pubitemid 350174935
136. Gambarin-Gelwan M, Wolf DC, Shapiro R, et al. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000;95(6):1535-8 (Pubitemid 30396316
137. Nakamura S, Nouso K, Sakaguchi K, et al. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101(9):2038-43 (Pubitemid 44337629
138. Yamashiki N, Sugawara Y, Tamura S, et al. Diagnostic accuracy of alpha-fetoprotein and des-gamma-carboxy prothrombin in screening for hepatocellular carcinoma in liver transplant candidates. Hepatol Res 2011;41(12):1199-207
139. Liu H, Li P, Zhai Y, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010;16(35):4410-15